A Trial to Evaluate the Effect of LEO 152020 on the Heart of Healthy People
Status:
Not yet recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
The trial medicine (LEO 152020) is being developed to treat people with eczema.
The aims of this trial are to find out about:
- How the trial medicine affects participant's heart rhythm.
- How much of the trial medicine is absorbed into the bloodstream, and how quickly the
body gets rid of it.
- The safety of the trial medicine and any side effects that might be related to it.
The trial will last up to 45 days, and there will be up to 6 visits.
Four treatment periods are planned for this trial. In each treatment period, participant will
receive a single dose of the trial medicine at dose A, trial medicine at dose B, dummy
tablet, or an approved medication named moxifloxacin (used for the treatment of bacterial
infections). The order of these 4 treatment periods is chosen at random. Participant will
receive all 4 treatments; it is only the order of the treatments that is random.
There will be 6 trial visits and they will include 1 screening visit, 4 treatment period
visits and 1 final, follow-up visit at the clinic. The 4 treatment period visits will last
for 3 days, from Day -1 (check-in to the clinic) to Day 2 (check-out of the clinic). There
will be a period of at least 3 days between the 4 dosing occasions.